Replies to post #714 on Mining Sector Ideas

[gfp927z]

Another T/A chart aspect right now is the large 'gap' from earlier this week. The S+P 500 gapped up from 4420 to 4460 (approx), and in T/A there is a general rule that all gaps are eventually filled, meaning that at some point the S+P 500 will have to come down to 4420 again to 'fill the gap', before resuming the bull market (assuming that's what we're in).

Anyway, with the current momentum, the S+P 500 might continue up to the July high (4600) before a meaningful pullback / consolidation occurs (which 'closes the gap'), or alternately, the current move stalls at the Sept high trading range (4510-4540) and pulls back. Or some variation - like a small pullback, followed by the move to 4600, and then the larger pullback to fill the gap. Either way the 4600 target is beckoning, though things are starting to get near term overextended, RSI near 70, etc.

But upward momentum should be a durable backdrop, since Wall St has gotten the 'green light' from the Fed to get back into stocks. Today G. Sachs made a call for a new all time highs next year, which does seems likely, so a simple buy/hold could be the best overall approach.



---

[gfp927z]

Bigworld, Here's the full Acurx conference call transcript (next post). Note - I made several obvious corrections, for example, they had 'Banco' instead of 'Vanco' for Vancomycin. Other apparent mistakes in the transcript I left as is. There were a lot fewer transcription mistakes than back in the 'old days' when I was following bio stocks, lol. But the key info and numbers in the transcript jive with my own notes taken from the audio call replay.

A few new (to me) tidbits from the Phase 2b trial -- there were apparently two patients who were dropped from the data due to 'protocol violations', although Luci said he doesn't know if they were from the Ibeza or Vanc arms of the trial.

One question I would have asked would be about the one (and only) clinical failure patient in the entire trial. The patient was in the Phase 2b, and in the Ibeza arm, so it would be informative to know more about the patient -- age, medical history, co-morbidities, etc, as well as more about the 'degree' of failure - was treatment almost successful, or did it miss by a mile, etc. But we may have to wait for the Phase 2b data to be published in a science journal before that info becomes available.

That single treatment failure (in the Ibeza arm) is what severely tanked the stock a few weeks ago when the Phase 2b press release came out, and what makes for some continued nagging doubts, considering that Vanc had 100% success in the trial. For Vanc to show 100% success shows how risky it is to base conclusions on such a tiny trial. And the upcoming sustained cure / reinfection and microbiome data will have similar shortcomings. Hopefully the upcoming data will be clear and unambiguous, but tiny trials can be extremely unpredictable.

I noticed that the tone of this conference call (compared to Luci's July investor presentation) makes it sound more likely that Acurx will need to do the first Phase 3 itself, or at least that's the impression I got. But we'll see how this upcoming data looks --> should be very interesting :o)



---

[gfp927z]

Bigworld, Concerning the overall stock market, one potential scenario that worries me is the possibility that we are being set up for a rug pull. Here's the basic scenario --

With malevolent foreknowledge, the Fed re-inflates the stock market for a period of weeks to give their globalist buddies (Blackrock, etc) a chance to exit and/or place bearish bets. Then the rug pull comes when a 'US bombs Iran' scenario plays out, justified by some type of false flag event, like a US warship being severely damaged or sunk in the region, blamed on Iran and/or their supposed proxies, like the Houthis.

For several weeks, the 'Houthis' (who are actually funded by the CIA, as was 'ISIS', similar to how the British funded the Muslim Brotherhood many decades ago), these 'Houthis' have already been lobbing cruise missiles and drones toward Israel and US warships in the Red Sea. The US ships have been shooting them down, but let's say one or more slip through, hit the US ship, and we have a Gulf of Tonkin staged event all over again, and a perfect justification for the US to bomb Iran. Under the above scenario, most everyone is in on it -- the Fed, the various warmonger factions, and the less enthusiastic govt / foreign policy figures acquiesce and go along with it. Variations on this scenario would remove Powell and the Fed from the war scheme, with their recent market juicing activities being motivated by other factors.

Just speculating here, but having followed the warmonger faction 'basement crazies' for some years now, it's hard to imagine that they won't use the current opportunity to bomb Iran and destroy at least some of the Iranian nuclear enrichment sites. The desire to do this is understandable, and there are articles almost every day about how close Iran is to having a nuclear weapon, and how their 60% enrichment status can be bumped up to the required 90% in a matter of weeks. While that may be somewhat exaggerated, there is absolutely no way that the current Netanyahu faction will ever allow this to happen. So, my conclusion is that one way or another, bombs will be falling on Iran in the months ahead. If a manufactured false flag event is required, so be it, but they are not going to let this opportunity slip away. Fwiw, I'm figuring the timeline will likely be by Spring, but just a guess.

Hopefully this assessment is wrong, but I did lower my stock allocation down from 12% to 5% today. With the stock market up 10% over the last several weeks, I figure that's good enough for now, and can tack on another 5% by just sitting safely in cash/T-Bills. Anyway, just some late night thoughts from a conspiracy addled brain..







---